FDA Approves Amneal Pharmaceuticals’ Albuterol Sulfate Inhalation Aerosol for Asthma and COPD Treatment

The U.S. Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ albuterol sulfate inhalation aerosol, a treatment commonly used for asthma and chronic obstructive pulmonary disease (COPD). This approval is expected to increase the availability of this medication for millions of individuals in the United States who rely on it to manage respiratory conditions.

Albuterol sulfate inhalation aerosol serves as a bronchodilator, helping to relax muscles in the airways and improve breathing. It is frequently prescribed for patients experiencing bronchospasms associated with asthma or COPD. The FDA’s decision allows Amneal Pharmaceuticals to manufacture and distribute this product, potentially expanding access to an essential treatment option for those managing these chronic respiratory diseases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Author

GOAI